StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
AEVS.SW$12.90-0.77%
Fair $12.90+0.0%

AEVS.SW

Aevis Victoria SA

Healthcare / Medical Care FacilitiesSwiss

$12.90

-0.10 (-0.77%)

Fairly Valued+0.0%Fair Value $12.90Fund rank 25/100 · Data gapFallback financials|
SA 10/F
F-Score: 5/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 16%

FCF escenarios

weak_data · normalized FCF $-18.8M · quality 37.0/100

Data gap 25/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 25/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

10/100

F

Piotroski

5/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is -3.9%, below the 5% threshold
Thesis & Journal · AEVS.SWLocal privado en este navegador · Aevis Victoria SA
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$1.1B

P/E

N/A

•

EV/EBITDA

23.9x

↑

ROE

-3.9%

↓

Gross Margin

80.1%

↑

Debt/Equity

1.86

↑
52-Week Range$13
$12$14

TradingView lightweight chart

AEVS.SW price, volumen y niveles de valoración

Último $12.90Periodo -86.8%
Fair value: $12.90

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+3.2%

FCF CAGR

-50.5%

FCF margin

0.4%

FCF / Net income

-0.24x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $1.20B · net income $-20.1M · FCF $4.9M

2022-FY → 2025-FY

Gross margin

80.1%+0.7% pts

Operating margin

-1.3%-1.9% pts

Net margin

-1.7%-7.1% pts

FCF margin

0.4%-3.3% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$1.20B$1.20B$1.01B$952.9M$1.09B
Net Income$-20.1M$-20.1M$-2.9M$-39.3M$58.8M
EBITDA$84.0M$84.0M$97.0M$53.5M$155.8M
EPS——-0.03-0.470.69
Gross Margin80.1%80.1%78.2%78.5%79.3%
Operating Margin-1.3%-1.3%-2.4%-2.3%0.6%
Net Margin-1.7%-1.7%-0.3%-4.1%5.4%
Balance Sheet
Debt/Equity1.861.862.022.042.07
Current Ratio0.670.67———
Cash Flow
Free Cash Flow$4.9M$4.9M$-18.8M$-66.1M$40.3M
Returns
ROE-3.9%-3.9%-0.5%-8.0%12.5%
Valuation
P/E————26.88
EV/EBITDA23.9223.9223.0642.6415.92
P/B2.142.142.262.763.38
Growth & Yield
Revenue Growth18.4%18.4%6.0%-12.4%—
EPS Growth——93.6%-168.1%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -6.2%

Total return

-6.2%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.03 → n/d

Residual

-6.2%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-6.2%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.